SAK 3 | CAS#1256269-87-0 | Ca channel activator

MedKoo Cat#: 584472 | Name: SAK 3

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SAK 3 is a potent CaV3.1/3.3 activator that is orally bioavailable.

Chemical Structure

SAK 3

CAS#1256269-87-0

Theoretical Analysis

MedKoo Cat#: 584472

Name: SAK 3

CAS#: 1256269-87-0

Chemical Formula: C20H23N3O4

Exact Mass: 369.1689

Molecular Weight: 369.42

Elemental Analysis: C, 65.03; H, 6.28; N, 11.37; O, 17.32

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 weeks
25mg	USD 850.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SAK 3; SAK3; SAK-3

IUPAC/Chemical Name

Ethyl 8'-methyl-2',4-dioxo-2-(piperidin-1-yl)-2'H-spiro[cyclopent[2]ene-1,3'-imidazo[1,2-a]pyridine]-3-carboxylate

InChi Key

WZHBYTVHUFURPY-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H23N3O4/c1-3-27-18(25)15-14(24)12-20(16(15)22-9-5-4-6-10-22)19(26)21-17-13(2)8-7-11-23(17)20/h7-8,11H,3-6,9-10,12H2,1-2H3

SMILES Code

O=C(C1=C(N2CCCCC2)C3(N4C=CC=C(C)C4=NC3=O)CC1=O)OCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SAK 3 enhances CaV3.1 and CaV3.3, but not CaV3.2 activity in vitro. SAK 3 elevates ACh levels in hippocampus. SAK 3 rescues impaired memory-related behaviors, promotes adult neurogenesis and displays antidepressant-like effects in OBX mice.

In vitro activity:

SAK 3 possessed protective properties against cholinergic deficit, suggesting that it has potential for Alzheimer’s disease treatment. In human neuroblastoma SH-SY5Y cells, SAK 3 inhibited scopolamine-induced cellular apoptosis, increases in ROS levels, decreases in choline acetyltransferase level, phosphorylation of NF-κB, activation of Akt, JNK and p38 intracellular signaling pathways, and elevation of proinflammatory cytokines IL-1β and IL-6. Reference: Cytotechnology. 2020 Feb;72(1):155-164. https://pubmed.ncbi.nlm.nih.gov/31933104/

In vivo activity:

SAK 3 could be a candidate for Alzheimer's disease treatment. SAK 3 significantly enhanced acetylcholine (ACh) release in the hippocampal CA1 region of naïve mice. Acute SAK 3 administration significantly enhanced hippocampal ACh levels in OBX mice, rescuing impaired memory-related behaviors. SAK 3-induced ACh releases were significantly blocked in the hippocampus from Cav3.1 knockout mice. Reference: Neuropharmacology. 2017 May 1;117:1-13. https://pubmed.ncbi.nlm.nih.gov/28093211/

	Solvent	mg/mL	mM	comments
Solubility
	DMSO	36.9	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 369.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Suthprasertporn N, Mingchinda N, Fukunaga K, Thangnipon W. Neuroprotection of SAK3 on scopolamine-induced cholinergic dysfunction in human neuroblastoma SH-SY5Y cells. Cytotechnology. 2020 Feb;72(1):155-164. doi: 10.1007/s10616-019-00366-7. Epub 2020 Jan 14. PMID: 31933104; PMCID: PMC7002707. 2. Scaltriti E, Launay H, Genois MM, Bron P, Rivetti C, Grolli S, Ploquin M, Campanacci V, Tegoni M, Cambillau C, Moineau S, Masson JY. Lactococcal phage p2 ORF35-Sak3 is an ATPase involved in DNA recombination and AbiK mechanism. Mol Microbiol. 2011 Apr;80(1):102-16. doi: 10.1111/j.1365-2958.2011.07561.x. Epub 2011 Feb 15. PMID: 21276096. 3. Dhanalakshmi C, Janakiraman U, Moutal A, Fukunaga K, Khanna R, Nelson MA. Evaluation of the effects of the T-type calcium channel enhancer SAK3 in a rat model of TAF1 deficiency. Neurobiol Dis. 2021 Feb;149:105224. doi: 10.1016/j.nbd.2020.105224. Epub 2020 Dec 24. PMID: 33359140; PMCID: PMC8230513. 4. Yabuki Y, Matsuo K, Izumi H, Haga H, Yoshida T, Wakamori M, Kakei A, Sakimura K, Fukuda T, Fukunaga K. Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer. Neuropharmacology. 2017 May 1;117:1-13. doi: 10.1016/j.neuropharm.2017.01.011. Epub 2017 Jan 16. PMID: 28093211.

In vitro protocol:

In vivo protocol:

1. Dhanalakshmi C, Janakiraman U, Moutal A, Fukunaga K, Khanna R, Nelson MA. Evaluation of the effects of the T-type calcium channel enhancer SAK3 in a rat model of TAF1 deficiency. Neurobiol Dis. 2021 Feb;149:105224. doi: 10.1016/j.nbd.2020.105224. Epub 2020 Dec 24. PMID: 33359140; PMCID: PMC8230513. 2. Yabuki Y, Matsuo K, Izumi H, Haga H, Yoshida T, Wakamori M, Kakei A, Sakimura K, Fukuda T, Fukunaga K. Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer. Neuropharmacology. 2017 May 1;117:1-13. doi: 10.1016/j.neuropharm.2017.01.011. Epub 2017 Jan 16. PMID: 28093211.

Yabuki et al (2017) Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer. Neuropharmacology 117 1 PMID: 28093211